<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002322</url>
  </required_header>
  <id_info>
    <org_study_id>210A</org_study_id>
    <secondary_id>M/3330/0018</secondary_id>
    <nct_id>NCT00002322</nct_id>
  </id_info>
  <brief_title>A Study of Different Doses of Atevirdine Mesylate Plus Zidovudine in HIV-Positive Patients</brief_title>
  <official_title>Randomized, Double-Blind, Placebo-Controlled Comparative Dose-Response Study of Two Doses of Atevirdine Mesylate (U-87201E) in Combination With Fixed Doses of Zidovudine (AZT) in HIV+ Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmacia and Upjohn</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To determine the tolerance and antiviral response of two different doses of atevirdine
      mesylate (U-87201E) in symptomatic HIV-positive patients with CD4 counts of 50-350 cells/mm3,
      who also take zidovudine (AZT).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients are randomized to 1 of 3 treatment groups: U-87201E at 1 of 2 doses or placebo
      administered every 8 hours. Patients must have taken AZT for at least 3 months prior to
      randomization.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atevirdine mesylate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Concurrent Medication:

        Allowed:

          -  Primary or secondary prophylaxis for opportunistic infections.

        Patients must have:

          -  HIV infection.

          -  Symptoms (currently or prior to enrollment) included in Category B or C of CDC
             classification, although THE FOLLOWING CURRENT ACUTE MEDICAL CONDITIONS ARE NOT
             ALLOWED:

          -  Cryptococcosis

          -  Pneumocystis carinii pneumonia

          -  Herpes zoster

          -  Histoplasmosis

          -  CMV

          -  Hepatic or renal disease

          -  Lymphoma.

          -  CD4 count 50 - 350 cells/mm3 within 14 days prior to study entry.

          -  Ongoing therapy with AZT at 500 - 600 mg total daily dose for at least 3 months prior
             to study entry.

          -  Consent of parent, guardian, or person with power of attorney if less than 18 years of
             age.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following conditions are excluded:

          -  Intolerance to AZT.

          -  Current diagnosis of malignancy for which systemic therapy will be required during the
             study.

        Concurrent Medication:

        Excluded:

          -  Any other investigational drugs.

        Prior Medication:

        Excluded:

          -  Cytotoxic chemotherapy within 1 month prior to study entry.

          -  Prior U-87201E or any other non-nucleoside antiretroviral medications, including but
             not limited to nevirapine, TIBO R-82150 or TIBO R-82913, L-697639 or L-696229,
             U-90152S, or any protease inhibitors.

          -  Antiretroviral agents other than AZT within 3 months prior to study entry.

        Required:

          -  AZT for at least 3 months prior to study entry. Present use of excessive alcohol or
             illicit drugs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Los Angeles County / Health Research Assoc / Drew Med Ctr</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCI Med Ctr</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92668</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Davies Med Ctr</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infectious Disease Research Institute Inc</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hosp</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>212052196</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston City Hosp / FGH-1</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Orange Veterans Administration Med Ctr</name>
      <address>
        <city>East Orange</city>
        <state>New Jersey</state>
        <zip>07018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Buckley Braffman Stern Med Associates</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mem Hosp of Rhode Island</name>
      <address>
        <city>Pawtucket</city>
        <state>Rhode Island</state>
        <zip>02860</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Park Plaza Hosp</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ TX San Antonio Health Science Ctr</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78284</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wisconsin Community - Based Research Consortium</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 1996</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>AIDS-Related Complex</keyword>
  <keyword>Antiviral Agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Atevirdine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

